Abstract

Nearly half of all pregnancies are unintended; thus, existing family planning options are inadequate. For men, the only choices are condoms and vasectomy, and most current efforts to develop new contraceptives for men impact sperm development, meaning that contraception requires months of continuous pretreatment. Here, we provide proof-of-concept for an innovative strategy for on-demand contraception, where a man would take a birth control pill shortly before sex, only as needed. Soluble adenylyl cyclase (sAC) is essential for sperm motility and maturation. We show a single dose of a safe, acutely-acting sAC inhibitor with long residence time renders male mice temporarily infertile. Mice exhibit normal mating behavior, and full fertility returns the next day. These studies define sAC inhibitors as leads for on-demand contraceptives for men, and they provide in vivo proof-of-concept for previously untested paradigms in contraception; on-demand contraception after just a single dose and pharmacological contraception for men.

Half of all pregnancies are unintended; thus, existing family planning options are inadequate. This proof-of-concept study validates an on-demand contraception strategy for men, showing high effectiveness in quickly and temporarily reducing male fertility in mice.

Details

Title
On-demand male contraception via acute inhibition of soluble adenylyl cyclase
Author
Balbach, Melanie 1 ; Rossetti, Thomas 1 ; Ferreira, Jacob 1 ; Ghanem, Lubna 1 ; Ritagliati, Carla 1 ; Myers, Robert W. 2 ; Huggins, David J. 3 ; Steegborn, Clemens 4   VIAFID ORCID Logo  ; Miranda, Ileana C. 5   VIAFID ORCID Logo  ; Meinke, Peter T. 6 ; Buck, Jochen 1   VIAFID ORCID Logo  ; Levin, Lonny R. 1   VIAFID ORCID Logo 

 Weill Cornell Medicine, Department of Pharmacology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
 Tri-Institutional Therapeutics Discovery Institute, New York, USA (GRID:grid.511444.1) 
 Tri-Institutional Therapeutics Discovery Institute, New York, USA (GRID:grid.511444.1); Weill Cornell Medicine, Department of Physiology and Biophysics, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
 University of Bayreuth, Department of Biochemistry, Bayreuth, Germany (GRID:grid.7384.8) (ISNI:0000 0004 0467 6972) 
 Memorial Sloan Kettering Cancer Center, and The Rockefeller University, Laboratory of Comparative Pathology, Weill Cornell Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
 Weill Cornell Medicine, Department of Pharmacology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Tri-Institutional Therapeutics Discovery Institute, New York, USA (GRID:grid.511444.1) 
Pages
637
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2776289277
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.